

BEST AVAILABLE COPY

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | |
|--|--|---|--|------------------------|
| (51) International Patent Classification ⁶ : | | A1 | (11) International Publication Number: | WO 95/18376 |
| G01N 33/543, 33/58 | | | (43) International Publication Date: | 6 July 1995 (06.07.95) |
| (21) International Application Number: | | PCT/GB94/02813 | | |
| (22) International Filing Date: | | 23 December 1994 (23.12.94) | | |
| (30) Priority Data: | | 9326451.3 24 December 1993 (24.12.93) GB | | |
| (71) Applicant (for all designated States except US): | | MULTILYTE LIMITED [GB/GB]; C/o Ventham & Company, 2nd floor, Kingsbourne House, 229-231 High Holborn, London WC1V 7DA (GB). | | |
| (72) Inventor; and | | | | |
| (75) Inventor/Applicant (for US only): | | EKINS, Roger, Philip [GB/GB]; Pondweed Place, Friday Street, Abinger, Common Dorking, Surrey RH5 6JR (GB). | | |
| (74) Agent: | | ARMITAGE, Ian, M.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB). | | |
| (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). | | | | |
| <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | | | | |

(54) Title: BACK-TITRATION ASSAY USING TWO DIFFERENT MARKERS



(57) Abstract

The present invention relates to a method and kit for determining the concentration of an analyte (6) in a liquid sample, using a binding agent (2) capable of binding the analyte (6) and first and second developing agents (8, 12), the first developing agent (8) capable of binding to unoccupied binding sites on the binding agent (2) and having a first marker (10), the second developing agent (12) capable of binding to the bound analyte or to the occupied binding sites and having a second marker (14) different from the first. The concentration of the analyte is determined by measuring the signals from the markers on first and second developing agents (8, 12). Thus, the method combines the competitive and non-competitive methods of the prior art and preferably has the advantage of extending the working range and/or sensitivity of the assay.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

BACK-TITRATION ASSAY USING TWO DIFFERENT MARKERS

Field of the Invention

5 The present invention relates to binding assays, eg for determining the concentration of analytes in liquid samples.

Background to the Invention

10 It is known to measure the concentration of an analyte, such as a drug or hormone, in a liquid sample by contacting the liquid with a binding agent having binding sites specific for the analyte, separating the binding agent having analyte bound to it and measuring a value representative of the proportion of the binding sites of the binding agent that are occupied by analyte (referred to as the fractional occupancy). Typically, the concentration of the analyte in the liquid sample can then be determined 15 by comparing the fractional occupancy against values obtained from a series of standard solutions containing known concentrations of analyte.

20 In the past, the measurement of fractional occupancy has usually been carried out by back-titration with a labelled developing reagent using either so-called competitive or 25 non-competitive methods.

30 In the competitive method, the binding agent having analyte bound to it is back-titrated, either simultaneously or sequentially, with a labelled developing agent, which is typically a labelled version of the analyte. The developing agent can be said to compete for the binding sites on the binding agent with the analyte whose 35 concentration is being measured. The fraction of the binding sites which become occupied with the labelled analyte can then be related to the concentration of the analyte as described above.

In the non-competitive method, the binding agent having analyte bound to it is back-titrated with a labelled developing agent capable of binding to either the bound analyte or the occupied binding sites on the binding agent. 5 The fractional occupancy of the binding sites can then be measured by detecting the presence of the labelled developing agent and, just as with competitive assays, related to the concentration of the analyte in the liquid sample as described above.

10 In both competitive and non-competitive methods, the developing agent is labelled with a marker to allow the developing agent to be detected. A variety of markers have been used in the past, for example radioactive isotopes, 15 enzymes, chemiluminescent markers and fluorescent markers.

20 In the field of immunoassay, competitive assays have in general been carried out in accordance with design principles enunciated by Berson and Yalow, for instance in "Methods in Investigative and Diagnostic Endocrinology" (1973), pages 111 to 116. Berson and Yalow proposed that in the performance of competitive immunoassays, maximum sensitivity is achieved if an amount of binding agent is used to bind approximately 30 to 50% of a low concentration 25 of the analyte to be detected. In non-competitive immunoassays, maximum sensitivity is generally thought to be achieved by using sufficient binding agent to bind close to 100% of the analyte in the liquid sample. However, in both cases immunoassays designed in accordance with these 30 widely-accepted precepts require the volume of the sample to be known and the amount of binding agent used to be accurately known or known to be constant.

35 In International Patent Application WO84/01031, I disclosed that the concentration of an analyte in a liquid sample can be measured by contacting the liquid sample with a small amount of binding agent having binding sites specific for

the analyte. In this method, provided the amount of binding agent is small enough to have only an insignificant effect on the concentration of the analyte in the liquid sample, it is found that the fractional occupancy of the 5 binding sites on the binding agent by the analyte is effectively independent of the volume of the sample.

This approach is further refined in EP304,202 which discloses that the sensitivity and ease of development of 10 the assays in WO84/01031 are improved by using an amount of binding agent less than $0.1V/K$ moles located on a small area (or "microspot") of a solid support, where V is the volume of the sample and K is the equilibrium constant of the binding agent for the analyte.

15 In both these references, the fractional occupancy of the binding agent by the analyte is measured using either a competitive or a non-competitive technique, as described above.

20 There is a continuing need to develop binding assays having greater sensitivity, but that can also accurately measure analyte concentrations across a wider working range.

25 Summary of the Invention

The present invention provides a method for determining the concentration of an analyte in a liquid sample comprising:

30 (a) contacting the liquid sample with a binding agent having binding sites specific for the analyte so that a fraction of the binding sites become occupied by the analyte;

35 (b) back-titrating the binding agent with first and second developing agents, the first developing agent capable of binding to unoccupied binding sites and having a first marker, the second developing agent capable of binding to the bound analyte or to the occupied binding

sites and having a second marker different from the first;

(c) measuring the signals produced by the first and second markers to provide a value representative of the fraction of the binding sites occupied by the analyte; and,

5 (d) comparing the value to corresponding values obtained from a series of standard solutions containing known concentrations of analyte to obtain the concentration of the analyte in the liquid sample.

10 Accordingly, the present invention provides a method of determining the concentration of an analyte which combines the competitive and non-competitive methods of the prior art. Preferably, this has the advantage of extending the working range over which an assay can provide results of a 15 desired precision. This is explained further below.

Conveniently, the first and second markers are radioactive isotopes, enzymes, chemiluminescent markers or fluorescent markers. The use of fluorescent dye markers is especially 20 preferred as the fluorescent dyes can be selected to provide fluorescence of an appropriate colour range (excitation and emission wavelength) for detection. Fluorescent dyes include coumarin, fluorescein, rhodamine and Texas Red. Fluorescent dye molecules having prolonged 25 fluorescent periods can be used, thereby allowing time-resolved fluorescence to be used to measure the strength of the fluorescent signal after background fluorescence has decayed. Latex microspheres containing fluorescent or other markers, or bearing them on their surface can also be 30 employed in this context. The signals from the markers can be measured using a laser scanning confocal microscope.

Typically, the binding agent is an antibody having binding 35 sites for an antigen. Alternatively, the binding agent maybe an oligonucleotide capable of binding to a target nucleic acid molecule, eg by having a complementary sequence to the target nucleic acid molecule.

Preferably, a small amount of binding agent is used in accordance with the "ambient analyte" techniques of WO84/01031, so that the volume of the liquid sample need not be known. As discussed above, the amount of binding agent should be sufficiently small so that it does not significantly disturb the ambient concentration of analyte in the liquid sample. The use of an amount of binding agent which binds less than 5% of the analyte is preferred. However, the use of a smaller amount of binding agent, e.g. to bind 2% or 1% of the analyte, further reduces the disturbance to the ambient concentration of the analyte and helps to minimise the error in determining the analyte concentration.

More conveniently, the use of a concentration of binding agent not greater than $0.1V/K$, where V is the volume of the sample applied to the test zone and K is the association constant for analyte binding to the binding agent (as described in EP304,202), ensures that this condition is fulfilled regardless of the analyte concentration.

In one embodiment of the present invention, the concentration of a plurality of different analytes can be simultaneously determined using a plurality of different binding agents each having binding sites specific for a given analyte. In this case, preferably the binding agent is immobilised on a support at a discrete location, eg as a microspot.

In this embodiment, the same first and second developing agents can be used to back-titrate the plurality of different binding agents, the discrete locations containing the different binding agents being distinguished apart by their location on the support. Thus, it is possible to use a universal pair of developing agents, with the advantage that only two species of marker need to be detected.

Further, the binding agent having binding sites specific for a particular analyte can be immobilised on a support at a plurality of locations so that a series of replicate measurements of the concentration of that analyte can be 5 made simultaneously.

Preferably, particularly when rapid measurements are required, and/or when sample volumes are in the order of 1ml or less, the locations are microspots having an area of 10 1mm². Furthermore, the binding agent should preferably be present at a high surface density within the microspot, thereby maximising sensitivity.

15 The present invention also includes a kit for determining the concentration of an analyte in a liquid sample according to the above method, the kit comprising:

- (a) a solid substrate having attached thereto binding agent, the binding agent having binding sites specific for the analyte,
- 20 (b) back-titration reagents comprising first and second developing agents, the first developing agent capable of binding to unoccupied binding sites and having a first marker, the second developing agent capable of binding to the bound analyte or to occupied binding sites 25 and having a second marker different from the first.

Brief Description of the Drawings

30 The present invention will now be further described by way of example with reference to the accompanying the schematic drawings in which:

Figure 1 shows a graph relating error in an assay to its working range, commonly termed the precision profile of the assay;

35 Figure 2 shows a competitive assay of the prior art;
Figure 3 shows a non-competitive assay of the prior art;

Figure 4 shows an example of an assay according to the present invention;

5 Figure 5 shows the response curves obtained by observing the signals emitted by the first developing agent reacting with unoccupied binding agent of the binding sites, and the second developing agent reacting with unoccupied binding sites; and,

10 Figure 6 shows a comparison of the precision profiles obtained by separate analysis of the competitive and non-competitive data, with the profile obtained when the data are combined by relying on ratio R_y , ie the ratio of the signals emitted by both developing agents.

Detailed Description

15

Figure 1 illustrates how the precision of an assay varies across its working range. This figure represents the precision profile of an assay, ie the curve relating the error (cv) in the analyte concentration measurement plotted 20 against analyte concentration. The working range of the assay comprises the range of analyte concentrations (between X and Y) within which assay results are of acceptable precision (typically better than 10%). Assay sensitivity is represented by the lower limit of detection, 25 which quantity is typically defined as the analyte concentration below which the cv of the analyte determination exceeds 100%.

30

However, the cv values used to define the working range and lower limit of detection of an assay are a matter of individual choice, and no generally accepted convention regarding these values exists in the field, notwithstanding widespread acceptance of the general concepts portrayed in figure 1.

35

A sensitive assay is implicitly designed to determine very low analyte concentrations with high precision, ie to yield

a very low detection limit. The effective sensitivity of the assay may also be represented by the lower limit of the working range, this value generally correlating closely with the lower limit of detection. Increasing assay 5 sensitivity implies that both the lower limit of detection and the lower limit of the working range (X) are reduced. However, it is common experience that increasing assay sensitivity has the concomitant and undesired effect of also decreasing the upper limit of the working range (Y). 10 In other words, an assay designed for high sensitivity is generally unsuitable for the accurate measurement of high analyte concentrations.

15 In figures 2 to 4, a binding agent 2 has been immobilised on a support 4. The binding agent has binding sites specific for an analyte 6. After contacting the binding agent 2 with a liquid sample containing the analyte 6, some of the analyte 6 becomes bound to the binding sites of the binding agent 2.

20 In figure 2, a developing agent 8 carrying a marker 10 binds to binding sites on the binding agent 2 unoccupied by analyte 6. The fractional occupancy of the binding sites of the binding agent 2 by the developing agent 8 can be 25 measured by detecting marker 10. This allows the concentration of the analyte 6 in the liquid sample to be ascertained by comparing the signal from the marker 10 against results obtained using a series of standard solutions containing known concentrations of analyte 6.

30 Figure 3 shows a non-competitive assay where the analyte 6 bound to the binding sites of the binding agent is detected by back-titrating with a developing agent 12 carrying a marker 14. The binding agent 2 can bind to the bound 35 analyte 6 or to the occupied binding sites of the binding agent. The fractional occupancy of the binding sites by the analyte can then be measured by detecting the marker

14. As with the competitive assay shown in figure 2, the signal from the marker 14 can be related to the concentration of the analyte 6 in the liquid sample by reference to the results obtained using a series of 5 solutions of known concentration.

Figure 4 shows an assay carried out in accordance with the present invention. After the binding agent 2 has been contacted with the analyte 6, a proportion of the binding 10 sites become occupied by analyte 6. The binding agent 2 is then back-titrated using first and second developing agents 8, 12, the developing agents being labelled with first and second markers 10, 14. The markers 10, 14 are chosen to provide distinguishable signals, for instance in the case 15 of fluorescent markers by choosing chromophores which emit light at different frequencies and/or with different fluorescence decay times.

The method of the present invention has some important 20 advantages over the prior art competitive or non-competitive assays.

Firstly, it is found that the use of two developing agents extends the working range over which a given binding assay 25 can be used. This is because at low analyte concentrations, the amount of non-competitive developing agent 12 carrying marker 14 and the detectability of marker 14 are the key determinants of the lower limit of the working range of the binding assay. In other words, very 30 low analyte concentrations are measured with greatest precision by determination of the signals generated by marker 14 carried on developing agent 12, the magnitude of the signals generated marker 10 carried on developing agent 8 being of lesser importance.

35

Conversely, at high analyte concentrations, it is found that the amount of competitive developing agent carrying

marker 10, and the detectability of marker 10, are of greatest importance in determining the upper limit of the working range of the binding assay. In other words, high analyte concentrations are measured with greatest precision 5 by observation of the signals generated by marker 10 carried on developing agent 8, the magnitude of the signals generated by marker 14 carried on developing agent 12 being of lesser importance.

10 Thus, by measuring the "specific" signals generated by both markers specifically-bound to the binding agent on the solid support, and by minimising the background signals (generated - for example - by developing reagents 8 and 12 non-specifically bound to the solid support) against which 15 the specific signals are determined, the lower limit of the working range can be minimised and the upper limit maximised, thereby extending the working range of the assay system, ie the range of analyte concentrations which can be measured with acceptable precision.

20 A further advantage arises as the sum of the signals emitted by the two markers when appropriately adjusted to allow for the differing efficiencies with which they are measured, provides a measure of the total amount of binding 25 agent present in the system. In the prior art, knowledge of the total amount of binding agent, or that it is constant, is often a requirement in carrying out assays. As considerable difficulties have been found in past in immobilising on surfaces constant amounts of binding agents 30 (eg antibodies) at even densities, by yielding a measure of both occupied and unoccupied sites, this method allows this problem to be overcome, and the total number of binding sites to be determined.

35 However, in assays carried out according to the present invention using a small amount of binding agent (eg to bind <5% of the analyte in the sample), it is found that the

ratio of the signals from the two markers is solely dependent on the analyte concentration. The basis of this observation is the finding disclosed in International Patent Application WO84/01031 that under such circumstances the fractional occupancy (F_y) of the binding sites is solely dependent on the ambient analyte concentrations.

Thus, if the total number of binding sites is X , for a given analyte concentration Y , $F_y X$ sites will be occupied, and $(1-F_y) X$ sites will be unoccupied. If the measurement efficiency of the signal generated by occupied sites is ϵ_1 , and of the signal generated by unoccupied sites is ϵ_2 , the ratio (R_y) of the signals generated from occupied and unoccupied sites is $\epsilon_1 F_y / \epsilon_2 (1-F_y)$, or $CF_y / (1-F_y)$, where $C = \epsilon_1 / \epsilon_2 = \text{constant}$. Since F_y is solely dependent on the ambient analyte concentration, and since C is constant for both unknown samples and standards, measurement of R_y yields a measure of Y irrespective of the exact value of X .

Nevertheless, the use of the ratio R_y as the response variable is not obligatory, and may indeed be disadvantageous in certain circumstances, eg when the variability in the amount of binding agent situated in the microspot is low, implying that the amount is essentially constant. In these circumstances, it may be preferable to process the competitive and non-competitive assay data separately. The fundamental advantages of combining both competitive and non-competitive assay strategies in accordance with the present invention are not lost thereby.

The method of the present invention also has wider applicability to cases where the amount of binding agent used is large, eg where more than 5% of the total amount of analyte present in the liquid sample is bound. In this case, the ratio of the signals from the two markers is dependent on both the analyte concentration and the amount of binding agent. However, as the amount of binding agent

can be determined from sum of the signals from the two markers, a simple correction can be made to obtain the analyte concentration in the sample from the ratio of the two signals.

5

Thus, the method of the present invention also avoids the necessity of knowing that a constant amount of binding agent is immobilised on different supports, as variations in the amount of binding agent immobilised can readily be corrected for.

10

Under these circumstances, the sample volume v must either be known or constant.

15

Let the signal emitted by the label marking the developing agent directed against occupied binding agent binding sites be given by S_o ;

20

and the signal emitted by the label marking the developing agent directed against unoccupied binding agent binding sites be given by S_u ;

25

and let the constants relating the respective signals to occupied and unoccupied sites be ϵ_o and ϵ_u respectively;

30

and K = the effective equilibrium constant governing the reaction between the analyte and binding agent.

35

Then, if the analyte concentration in a sample is given by y ;

$$Y = (S_o/\epsilon_o) [\epsilon_u/(KS_u) + 1/v]$$

35

Assuming v is known, this equation contains two unknown constants, ϵ_o and ϵ_u/K . By determining the signals S_o and S_u for a series of known analyte concentrations, these constants can be determined, and unknown analyte concentrations estimated from corresponding determinations

of S_0 and S_u .

Under ambient analyte conditions, the term $1/v$ becomes negligible, and S_0/S_u is proportional to the ambient analyte concentration.

Example

Reagents:

- 10 1. Fluorescent hydrophilic latex microspheres, $0.227\mu\text{m}$ diameter (Ex 642nm, Em 653nm) from Boehringer Mannheim.
2. Sulfate FluoSpheres, $0.1\mu\text{m}$ diameter (Ex 490, Em 515nm) from Molecular Probes.
- 15 3. Glycine, Tween20, MES (2-[N-Morpholino] ethanesulfonic acid), di-sodium hydrogen orthophosphate anhydrous, sodium di-hydrogen orthophosphate, ethyl-3 (3-dimethyl amino) propyl carbodimide hydrochloride, RIA grade bovine serum albumin, Trizma and sodium azide from Sigma.
- 20 4. Thyroid stimulating hormone (TSH) from NIH USA.
5. Anti-TSH monoclonal capture and developing antibodies from Boehringer Mannheim.

25 **Conjugation of Anti-TSH Mouse Monoclonal Antibody to Fluorescent Hydrophilic Latex Microspheres**

1. 10mg of fluorescent hydrophilic latex microspheres in 0.5ml double distilled water were added to 0.5ml of 1% Tween20, shaken for 15 min at room temperature and centrifuged at 8°C for 10min at 20,000rpm in a TSE High-Spin 20 ultracentrifuge.
- 30 2. The pellet was dispersed in 2ml of 0.05M MES (2-[N-Morpholino] ethanesulfonic acid) buffer, pH6.1 and centrifuged.
- 35 3. Step 2 was repeated.
4. The pellet was dispersed in 0.8ml MES buffer.
5. 2mg of anti-TSH monoclonal developing antibody in

100 μ l were added to the microspheres and shaken for 15min at room temperature.

6. 100 μ l of 0.25% ethyl-3 (3-dimethyl amino) propyl carbodiimide hydrochloride were added to the mixture and shaken for 2 hours at room temperature.
- 5 7. 10mg glycine in 100 μ l of MES buffer were added to the mixture, shaken for a further 30min and centrifuged.
8. The pellet was dispersed in 2ml of 1% BSA, shaken for 1 hour at room temperature and centrifuged.
- 10 9. The pellet was dispersed in 2ml of 1% BSA, shaken for 1 hour at room temperature and centrifuged.
10. The pellet was dispersed in 2ml of 0.1M phosphate buffer, pH7.4 and centrifuged.
11. Step 10 was repeated twice.
- 15 12. The pellet was dispersed in 2ml of 1% BSA containing 0.1% sodium azide and stored at 4°C.

Adsorption of TSH to Yellow/Green Sulfate FluoSpheres

- 20 1. 50mg of TSH in 50 μ l were added to 4mg of sulfate FluoSpheres in 350 μ l of 0.1M phosphate buffer, pH7.4 and shaken overnight at room temperature.
2. The preparation was centrifuged at 20,000rpm, for 15min at 8°C in a MSE High-Spin 20 ultracentrifuge.
- 25 3. The pellet was dispersed in 2ml of 1% BSA, shaken for 1 hour and centrifuged.
4. The pellet was dispersed in 2ml of 0.5% Tween20, shaken for 30 min and centrifuged.
5. The pellet was dispersed in 2ml of phosphate buffer and centrifuged.
- 30 6. Step 4 was repeated twice.
7. The pellet was dispersed in 2ml of 1% BSA containing 0.1% sodium azide and stored at 4°C.

A Combined Competitive and Non-competitive Microspot Sandwich TSH Assay

- 5 1. Capture anti-TSH antibody microspots were made by depositing a single $0.5\mu\text{l}$ droplet of the antibody at a concentration of $200\mu\text{g/ml}$ in 0.1M phosphate buffer, pH7.4 on each of the black Dynatech MicroFluor microtitre wells. The droplets were aspirated immediately.
- 10 2. The wells were flooded with 1% BSA, shaken for 1 hour and washed with phosphate buffer.
3. $200\mu\text{l}$ of TSH standards ($0, 0.01, 0.03, 0.1, 0.3, 1.0, 3.0, 10, 30, 75, 150$ & $300\mu\text{U/ml}$) were added to duplicate wells, these were shaken for 2 hours and washed with phosphate buffer containing 0.05% Tween20.
- 15 4. $200\mu\text{l}$ of $50\mu\text{g/ml}$ anti-TSH developing antibody conjugated hydrophilic microspheres for measuring occupied antibody binding sites were added to all wells, these were shaken for 1 hour and washed with phosphate-Tween20 buffer.
- 20 5. $200\mu\text{l}$ of $50\mu\text{g/ml}$ TSH-conjugated sulfate microspheres for measuring unoccupied antibody binding sites were added to all wells, these were shaken for 1 hour, washed with phosphate-Tween20 buffer and scanned with a laser scanning confocal microscope.

25 25 Figure 5 portrays the response curves obtained by observing the signals emitted by the second developing agent (a labelled antibody) reacting with occupied "sensor" antibody binding sites, and the first developing agent (labelled TSH) reacting with unoccupied binding sites. The signals from the first and second markers may be combined to give the ratio R_y , which is plotted against analyte concentration. Thus, figure 5 shows that the variation of R_y with analyte concentration is smooth over a wide range of analyte concentrations, ie the working range of the assay

30 30 is greater than the prior art competitive or non-competitive methods.

Figure 6 shows a comparison of the precision profiles obtained by separate statistical analysis of the competitive and non-competitive data, with the profile obtained when the data are combined by relying on the ratio 5 R_y as the response variable, as discussed above.

Note that the working ranges of both the non-competitive (A to C) and competitive (D to E) assays are considerably more restricted than that of the combined assay which extends 10 from B to above 1000 μ U/ml.

This graph also illustrates a phenomenon which may make 15 reliance on the ratio R_y disadvantageous in certain circumstances. However, in these circumstances it is possible to process the data in a different manner. This phenomenon (the lower precision obtained over certain parts 20 of the range by relying on the ratio as compared with that obtained by processing the data separately) stems from the fact that the statistical error in the ratio may be significantly greater than that in one of the individual 25 measurements, particularly if the amount of binding agent in the microspot is constant. Under the circumstances, samples containing low analyte concentrations may be determined by reliance on the non-competitive data, and high analyte concentrations by reliance on the competitive data.

CLAIMS:

1. A method for determining the concentration of an analyte in a liquid sample comprising:
 - 5 (a) contacting the liquid sample with a binding agent having binding sites specific for the analyte so that a fraction of the binding sites become occupied by the analyte;
 - 10 (b) back-titrating the binding agent with first and second developing agents, the first developing agent capable of binding to unoccupied binding sites and having a first marker, the second developing agent capable of binding to the bound analyte or to the occupied binding sites and having a second marker different from the first;
 - 15 (c) measuring the signals produced by the first and second markers to provide a value representative of the fraction of the binding sites occupied by the analyte; and,
 - 20 (d) comparing the value to corresponding values obtained from a series of standard solutions containing known concentrations of analyte to obtain the concentration of the analyte in the liquid sample.
2. A method according to claim 1 wherein a small amount of binding agent is used, so that the ambient concentration of analyte in the sample is not significantly disturbed.
3. A method according to claim 2 wherein the small amount of binding agent is less than $0.1V/K$ moles, where V is the volume of the liquid sample and K is the association constant for analyte binding to the binding agent.
4. A method according to any one of the preceding claims for determining the concentration of a plurality of different analytes in the liquid sample, using a plurality of binding agents, each binding agent having binding sites specific for a given analyte.

5. A method according to any one of the preceding claims wherein the binding agent is immobilised on a support at a discrete location.

5 6. A method according to claim 5 wherein, in an assay for a plurality of binding agents, the same first and second developing agents are used to back-titrate the plurality of different binding agents, the discrete locations containing the different binding agents being distinguished apart by 10 their location on the support.

15 7. A method according to any one of the preceding claims wherein binding agent having binding sites specific for a particular analyte is immobilised on a support at a plurality of discrete locations so that a series of 15 measurements of the concentration of that analyte are obtained.

20 8. A method according to any one of claims 5 to 7 wherein the discrete location is a microspot.

25 9. A method according to claim 8 wherein the microspots have an area of less than 1mm².

25 10. A method according to any one of the preceding claims wherein the binding agent is an antibody having binding sites for an antigen or an oligonucleotide capable of binding to a nucleic acid analyte.

30 11. A kit for determining the concentration of an analyte in a liquid sample according to the method of any one of the preceding claims, the kit comprising:
(a) a solid substrate having attached thereto binding agent, the binding agent having binding sites specific for the analyte,
35 (b) back-titration reagents comprising first and second developing agents, the first developing agent

capable of binding to unoccupied binding sites and having a first marker, the second developing agent capable of binding to the bound analyte or to occupied binding sites and having a second marker different from the first.

1/4







Fig.1.

2/4



3/4




Fig. 5.

614




Fig. 6.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/02813A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/543 G01N33/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| Y | WO,A,88 01058 (R. PH. EKINS) 11 February 1988 see the whole document ---- | 1-11 |
| Y | WO,A,88 09503 (THE MCLEAN HOSPITAL CO.) 1 December 1988 see the whole document ---- | 1-11 |
| A | WO,A,84 01031 (R. PH. EKINS) 15 March 1984 cited in the application ---- | |
| A | EP,A,0 304 202 (R. PH. EKINS) 22 February 1989 cited in the application ---- | |

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

19 April 1995

Date of mailing of the international search report

10.05.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentzaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Cartagena y Abella, P

INTERNATIONAL SEARCH REPORT

Information on patent family

International Application No

PCT/GB 94/02813

| Patent document referred in search report | Publication date | Patent family member(s) | | Publication date |
|--|---------------------|----------------------------|----------|---------------------|
| WO-A-8801058 | 11-02-88 | AU-B- | 614935 | 19-09-91 |
| | | AU-A- | 7755987 | 24-02-88 |
| | | FI-C- | 92881 | 10-01-95 |
| | | FI-B- | 92881 | 30-09-94 |
| | | JP-T- | 1503405 | 16-11-89 |
| | | US-A- | 5171695 | 15-12-92 |
| | | CA-A- | 1284620 | 04-06-91 |
| | | DE-A- | 3784465 | 08-04-93 |
| | | EP-A, B | 0271974 | 22-06-88 |
| | | EP-A- | 0318491 | 07-06-89 |
| WO-A-8809503 | 01-12-88 | US-A- | 5098846 | 24-03-92 |
| | | EP-A- | 0359780 | 28-03-90 |
| WO-A-8401031 | 15-03-84 | AU-A- | 1944283 | 29-03-84 |
| | | EP-A, B | 0134215 | 20-03-85 |
| | | JP-B- | 6064059 | 22-08-94 |
| | | JP-T- | 59501480 | 16-08-84 |
| EP-A-0304202 | 22-02-89 | AU-A- | 2253488 | 01-03-89 |
| | | DE-A- | 3872621 | 13-08-92 |
| | | EP-A- | 0375700 | 04-07-90 |
| | | FI-B- | 92110 | 15-06-94 |
| | | WO-A- | 8901157 | 09-02-89 |
| | | CA-A- | 1334278 | 07-02-95 |
| | | JP-T- | 3503081 | 11-07-91 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.